Document Detail

Perspectives gained from large-scale thrombolytic comparative trials.
MedLine Citation:
PMID:  11824006     Owner:  NLM     Status:  MEDLINE    
Four thrombolytic comparative trials without a placebo arm have each been conducted in populations of more than 1000 patients: GISSI-2 International, ISIS-3, GUSTO, and INJECT. The treatment strategy associated with use of intravenous heparin and the accelerated regimen of tissue plasminogen activator (t-PA) accounts for the differences between the results of GUSTO and those of the earlier studies of GISSI-2 International and ISIS-3. Using analysis of predefined parameters, it is possible to identify those subsets of patients most likely to benefit from accelerated administration of t-PA. A useful profile of patients at risk for intracranial haemorrhage has also been derived; this profile enhances efficient, sensible, individualized decision making. Results from the angiographic substudy of GUSTO highlight the fundamental importance of early coronary artery patency as a determinant of improved left ventricular function and survival and reaffirm the usefulness of left ventricular function as a surrogate measure for assessing the efficacy of novel reperfusion strategies. In addition, the opportunity to evaluate international differences in practice patterns, coupled with measures of quality of life and return to work, has given new insight into the importance of these issues in the care of patients with acute myocardial infarction. Future investigation must address the challenge of optimal use of resources in assessing novel therapies. Strategies include logistic modelling, surrogate end-points, sample enrichment with high-risk subsets, blended end-points, and uneven randomization.
P W Armstrong
Related Documents :
19436656 - Review of tenecteplase (tnkase) in the treatment of acute myocardial infarction.
9594336 - Evaluation of the patency rate of infarct-related artery after intravenous urokinase in...
11535716 - Hyperactivity of 99mtc-hmpao within 6 hours in patients with acute ischemic stroke.
849256 - Salivary peroxidase (sapx): genetic modification and relationship to the proline-rich (...
1449916 - Changes in left ventricular function and wall thickness in heart transplant recipients ...
8236346 - Cerebellar infarction. clinical and neuroimaging analysis in 293 patients. the tohoku c...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  European heart journal     Volume:  17 Suppl E     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  2002-02-04     Completed Date:  2002-02-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  9-13     Citation Subset:  IM    
Division of Cardiology, Department of Medicine, 2F1.30 WMC, University of Alberta, Edmonton, Alberta, Canada T6G 2R7.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrinolytic Agents / therapeutic use*
Myocardial Infarction / prevention & control*
Myocardial Reperfusion
Quality of Life
Randomized Controlled Trials as Topic / standards*
Ventricular Function, Left
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The future of thrombolysis in the treatment of acute myocardial infarction.
Next Document:  Health in Barbados in the 20th century.